{"type":"trials","record":{"id":42098,"source_id":"clinicaltrials-gov","external_id":"NCT02204683","title":"Pharmacokinetic Study of Intravitreal Aflibercept Injection in Eyes With Wet Age-related Macular Degeneration","brief_summary":"The main goal is to study way that aflibercept injection behaves in the eye and in the body of patients with wet macular degeneration, in patients who have had previous vitreous removal surgery.","overall_status":"Completed","phases":["PHASE1"],"study_type":"INTERVENTIONAL","sponsor":"University of Nebraska","enrollment":5,"countries":["United States"],"start_date":"2014-09-05","completion_date":"2016-12-14","last_update_date":"2023-09-06","source_url":"https://clinicaltrials.gov/study/NCT02204683","editorial_summary":"A registered PHASE1 study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.","first_seen_at":"2026-09-25T01:25:30.378222+00:00","last_seen_at":"2026-09-25T06:20:47.789+00:00","metadata":{"sex":"ALL","acronym":"DRAW","age_range":"50 Years","comparator":null,"organization":"University of Nebraska","interventions":["Aflibercept"],"registry_source":"ClinicalTrials.gov","outcome_measures":["Pharmacokinetic (PK) aflibercept aqueous — 28 days","PK Aflibercept plasma — 28 days"],"design_description":"NON RANDOMIZED · SINGLE GROUP · OTHER · NONE","source_has_results":false},"controlled_terms":["Neovascular Macular Degeneration","Aflibercept"],"relevance_confidence":80,"source_quality_score":100,"freshness_score":50,"publication_state":"published","match_explanation":"Title contains controlled term: age-related macular degeneration.","quality_checked_at":"2026-09-25T06:20:59.355028+00:00","duplicate_cluster_key":"id:nct02204683","duplicate_of_id":null,"evidence_snapshot":{"status":"structured","version":1,"duration":"2014-09-05 to 2016-12-14","comparator":null,"confidence":"structured-source","population":"ALL · 50 Years","provenance":{"duration":"start_date and completion_date","comparator":"registry arm fields","population":"registry eligibility fields","intervention":"registry intervention fields","participants":"enrollment","study_design":"study_type and registry design fields","evidence_stage":"phases","reported_outcome":"not available","outcomes_measured":"registry outcome-measure fields"},"generated_at":"2026-09-25T06:20:47.920Z","intervention":["Aflibercept"],"participants":5,"study_design":"NON RANDOMIZED · SINGLE GROUP · OTHER · NONE","subject_scope":"Human clinical study registration","evidence_stage":"PHASE1","safety_context":"Eligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians.","source_support":"Structured registry protocol metadata; no finding-level conclusion is generated.","main_limitation":"This is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.","reported_outcome":null,"outcomes_measured":["Pharmacokinetic (PK) aflibercept aqueous — 28 days","PK Aflibercept plasma — 28 days"],"regulatory_context":"Trial registration is not regulatory approval and does not establish that an intervention is available."},"clinical_trial_topics":[{"topic_slug":"vision-aging","is_published":true,"match_reasons":["Title contains controlled term: age-related macular degeneration.","Title supplies longevity context: age-related.","Study type is explicitly identified as INTERVENTIONAL."],"matched_fields":["title","title context","study type"],"relevance_score":80,"intelligence_topics":{"name":"Vision ageing","slug":"vision-aging"}}],"content_sources":{"name":"ClinicalTrials.gov","homepage_url":"https://clinicaltrials.gov/"}},"canonical_url":"https://www.immortal.life/trials/42098","automation_disclosure":"Generated automatically from cited source metadata. No scientist, clinician, researcher, editor, or human reviewer evaluates this publication before release."}